Pharma Report Profile

1. Gilead Sciences


Gilead's current and future success lies in the hands of its antiviral franchise.

2. Johnson & Johnson


J&J has earmarked a pile of cash — in the neighborhood of $18.5 billion — for future acquisition targets, but is patiently pacing the sidelines for the best players to walk onto the field.

3. Merck


Merck's landmark approval in 2015 was for immunotherapy Keytruda, which was cleared in October as a second-line treatment for the most common form of skin cancer.

4. Novartis


There are two primary reasons Novartis anticipates flat sales during 2016: Its hallmark cancer drug Gleevec recently came off patent and its Alcon ophthalmic business has seen declining growth rates.

5. Pfizer


Pfizer's dream to shave the top off a rising U.S. tax bill — and level the playing field with overseas competitors — was dashed.

6. AstraZeneca


AstraZeneca has embarked on what's likely to be a long, rough ride.

7. Teva


Analysts agree that Teva is casting a healthy financial shadow.

8. Amgen


As Amgen executives continue to toast a spectacular 2015 performance — double-digit growth from five of eight blockbusters — CEO Robert Bradway has cast a keen eye on the biotech pioneer's future.

9. Roche


On the sales and profit forecast front, analysts say that Roche missed the mark in 2015.

10. Sanofi


The big news: Sanofi and its partner Regeneron received approval for the first PCSK9 inhibitor to come to market in the U.S.: Praluent. But Praluent's sales to date haven't awed analysts.

11. Allergan


Allergan and Pfizer agreed to scrap their pending mega-merger following an early April power play by the U.S. government.

12. AbbVie


Coming off what AbbVie's board dubbed an "exceptional year," 2016 may sting.

13. Eli Lilly


Diabetes drugs headlined Eli Lilly's 2015 results, with Humalog and Trulicity contributing mightily to the upward sales curve.

14. Novo Nordisk


Novo Nordisk wants to own the obesity space much in the same way that it has attempted to dominate diabetes.

15. GlaxoSmithKline


The year 2015 was one of restructuring for GlaxoSmithKline.

16. Boehringer Ingelheim


In an effort to overcome pricing pressures and bounce back from patent losses, Germany's second-largest drugmaker has unloaded assets and reshuffled its management team.

17. Mylan


After turning its back on an offer from generics competitor Teva, Mylan stepped up with an unsuccessful hostile takeover bid for generic drugmaker Perrigo.

18. Biogen


Biogen's 2015 was hindered by less-than-stellar sales of its flagship multiple sclerosis treatment Tecfidera.

19. Valeant


So, heard anything lately about Valeant? Yeah. Even by the standards of an industry under siege, Valeant experienced quite the tumultuous last year or so.

20. Bristol-Myers Squibb


Immuno-oncology was the story at Bristol-Myers Squibb in 2015.


How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Who Needs a Gold Watch, Anyway?


Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.